Key terms

About AUTL

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest AUTL news

Apr 12 6:06am ET Buy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive Outlook by TipRanks Apr 02 7:16am ET Autolus Therapeutics announces acceptance of MAA by EMA for obe-cel by TipRanks Apr 01 7:22am ET Autolus Therapeutics Announces Board Leadership Changes by TipRanks Apr 01 7:19am ET Autolus chairman John Johnson steps down, Mike Bonney succeeds by TipRanks Mar 28 4:22pm ET Autolus files to sell 33.33M American Depositary Shares for holders by TipRanks Mar 25 8:41am ET Aveo Oncology appoints Edgar Braendle as CMO by TipRanks Mar 18 9:22am ET Autolus Therapeutics price target raised to $10 from $9 at Truist by TipRanks Mar 14 1:40pm ET Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL) by TipRanks Mar 14 12:42pm ET Autolus Therapeutics Announces Annual Results and CDO Resignation by TipRanks Mar 12 7:28am ET Autolus Therapeutics receives MHRA certification for Nucleus site by TipRanks Mar 11 7:08am ET Autolus Therapeutics announces publication in Blood Cancer Journal by TipRanks Feb 22 7:21am ET Autolus Therapeutics announces publication in Nature Communications by TipRanks Feb 13 4:26pm ET Autolus Therapeutics Shares Updated Corporate Insights by TipRanks Feb 12 6:35am ET Autolus Therapeutics: Strengthened by Strategic Collaboration and Upgraded Price Target by TipRanks Feb 09 5:20am ET Analysts’ Top Healthcare Picks: Merck & Company (MRK), Omnicell (OMCL) by TipRanks Feb 09 4:51am ET Autolus Therapeutics Announces New Offering Expectations by TipRanks Feb 09 4:51am ET Autolus Therapeutics Inks Major $350M Underwriting Deal by TipRanks Feb 09 4:03am ET Autolus Therapeutics Announces BioNTech Agreement Details by TipRanks Feb 09 4:02am ET Autolus Therapeutics’ Private Placement Raises Capital by TipRanks Feb 09 4:02am ET Autolus Therapeutics Strikes Major Deal with BioNTech by TipRanks Feb 08 5:35pm ET Neutral Outlook for Autolus Therapeutics Amid BioNTech Collaboration and Reduced M&A Speculation by TipRanks Feb 08 7:19am ET Autolus Therapeutics prices 58.3M ADSs at $6.00 in underwritten public offering by TipRanks Feb 08 6:05am ET Autolus Therapeutics files automatic mixed securities shelf by TipRanks Feb 08 5:49am ET BioNTech, Autolus Therapeutics announce strategic alliance by TipRanks Jan 27 4:13am ET Autolus Therapeutics’ CAR T Therapy FDA Application Accepted by TipRanks Jan 23 7:03am ET Autolus Therapeutics announces publication in ACS Chemical Biology by TipRanks Jan 23 6:08am ET Wells Fargo Gives a Buy Rating to Autolus Therapeutics (AUTL) by TipRanks Jan 22 7:45pm ET Autolus Therapeutics Poised for Growth: Buy Rating and $12 Price Target Backed by Strong Pipeline and Regulatory Milestones by TipRanks Jan 22 2:47pm ET Buy Rating Reiterated for Autolus Therapeutics Amid Positive Regulatory Developments and Growth Potential by TipRanks Jan 22 7:05am ET Autolus Therapeutics announces acceptance of BLA for obe-cel by TipRanks

No recent press releases are available for AUTL

AUTL Financials

1-year income & revenue

Key terms

AUTL Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

AUTL Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching